Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Harvard Business School
McKinsey
Express Scripts
Colorcon

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,078,388

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,078,388
Title:DNA vaccines for farm animals, in particular bovines and porcines
Abstract: DNA vaccine against a pathogen affecting farm animals, in particular bovines or porcines, comprising a plasmid containing a nucleotide sequence encoding an immunogen of a pathogen of the animal species considered, under conditions allowing the in vivo expression of this sequence, and a cationic lipid containing a quaternary ammonium salt, of formula ##STR00001## in which R1 is a saturated or unsaturated linear aliphatic radical having 12 to 18 carbon atoms, R2 is another aliphatic radical containing 2 or 3 carbon atoms, and X a hydroxyl or amine group, this lipid being preferably DMRIE.
Inventor(s): Audonnet; Jean-Christophe Francis (Lyons, FR), Fischer; Laurent Bernard (Sainte Foy les Lyon, FR), Barzu-Le-Roux; Simona (Lentilly, FR)
Assignee: Merial (Lyons, FR)
Application Number:09/760,574
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,078,388
Patent Claims:1. A DNA vaccine against a bovine pathogen, wherein the bovine pathogen is BRSV, BVDV-1, BVDV-2 or bPI-3, comprising at least one plasmid that contains and expresses in a bovine host cell a nucleotide sequence encoding an immunogen of the bovine pathogen, and a cationic lipid containing a quaternary ammonium salt, of the formula ##STR00003## in which R.sub.1 is a saturated or unsaturated linear aliphatic radical having 12 to 18 carbon atoms, R.sub.2 is an aliphatic radical containing 2 or 3 carbon atoms, and X a hydroxyl or amine group.

2. The vaccine according to claim 1, further comprising DOPE.

3. The vaccine according to claim 1, further comprising bovine GM-CSF.

4. The vaccine according to claim 2, further comprising bovine GM-CSF.

5. The vaccine according to claim 1, further comprising an expression vector that contains and expresses in a bovine host cell a nucleotide sequence encoding bovine GM-CSF.

6. The vaccine according to claim 2, further comprising an expression vector that contains and expresses in a bovine host cell a nucleotide sequence encoding bovine GM-CSF.

7. The vaccine according to claim 5, wherein the expression vector is a plasmid.

8. The vaccine according to claim 6, wherein the expression vector is a plasmid.

9. The vaccine according to claim 1, wherein the nucleotide sequence encoding the immunogen of the bovine pathogen has deleted therefrom a portion encoding a transmembrane domain.

10. The vaccine according to claim 1, wherein the plasmid further contains and expresses in a bovine host cell a nucleotide sequence encoding a heterologous tPA signal sequence.

11. The vaccine according to claim 1, wherein the plasmid further contains a stabilizing intron.

12. The vaccine according to claim 11, wherein the intron is intron II of a rabbit beta-globin gene.

13. The vaccine according to claim 1, wherein the bovine pathogen is bovine respiratory syncitial virus (BRSV).

14. The vaccine according to claim 13, wherein the immunogen is BRSV F, modified by substitution of the BRSV F signal sequence with a human tPA signal sequence, and/or by deletion of the transmembrane domain.

15. The vaccine according to claim 13, the immunogen is BRSV G, modified by substitution of the BRSV G signal sequence with a human tPA signal sequence, and/or by deletion of the transmembrane domain.

16. The vaccine according to claim 2 comprising a first plasmid that contains and expresses in a bovine host cell a nucleotide sequence encoding bovine respiratory syncitial virus (BRSV) F, modified by substitution of the BRSV F signal sequence with a human tPA signal sequence and deletion of the transmembrane domain and contiguous C-terminal portion; and a second plasmid that contains and expresses in a bovine host cell a nucleotide sequence encoding BRSV G, modified by substitution of the BRSV G signal sequence with a human tPA signal sequence and deletion of the transmembrane domain and contiguous C-terminal portion; and wherein the lipid is DMRIE, whereby the vaccine comprises DMRIE-DOPE.

17. The vaccine according to claim 9, further comprising DOPE.

18. The vaccine according to claim 9, further comprising bovine GM-CSF.

19. The vaccine according to claim 9, further comprising an expression vector that contains and expresses in a bovine host cell a nucleotide sequence encoding bovine GM-CSF.

20. The vaccine according to claim 19, wherein the expression vector is a plasmid.

21. The vaccine according to claim 10, further comprising DOPE.

22. The vaccine according to claim 10, further comprising bovine GM-CSF.

23. The vaccine according to claim 10, further comprising an expression vector that contains and expresses in a bovine host cell a nucleotide sequence encoding bovine GM-CSF.

24. The vaccine according to claim 23, wherein the expression vector is a plasmid.

25. The vaccine according to claim 11, further comprising DOPE.

26. The vaccine according to claim 11, further comprising bovine GM-CSF.

27. The vaccine according to claim 11, further comprising an expression vector tat contains and expresses in a bovine host cell a nucleotide sequence encoding bovine GM-CSF.

28. The vaccine according to claim 27, wherein the expression vector is a plasmid.

29. The vaccine according to claim 13, further comprising DOPE.

30. The vaccine according to claim 13, further comprising bovine GM-CSF.

31. The vaccine according to claim 13, further comprising an expression vector that contains and expresses in a bovine host cell a nucleotide sequence encoding bovine GM-CSF.

32. The vaccine according to claim 31, wherein the expression vector is a plasmid.

33. The vaccine of claim 13 wherein the immunogen is BRSV F.

34. The vaccine of claim 13 wherein the immunogen is BRSV G.

35. The vaccine according to claim 1 or 2 wherein the lipid is DMRIE.

Summary for Patent:   See Pricing

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France00 00798Jan 21, 2000

Details for Patent 7,078,388

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   See Pricing Merial (Lyons, FR) 2020-01-21 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   See Pricing Merial (Lyons, FR) 2020-01-21 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   See Pricing Merial (Lyons, FR) 2020-01-21 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Johnson and Johnson
AstraZeneca
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.